Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza virus infection.

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Zanamivir

Criteria

Inclusion Criteria:

• Subjects who meet the study population criteria

Exclusion Criteria:

• Subjects with a history of hypersensitivity to the ingredients of zanamivir